Brokerages Set MiNK Therapeutics, Inc. (NASDAQ:INKT) Price Target at $37.50

MiNK Therapeutics, Inc. (NASDAQ:INKT) has received a consensus recommendation of “Hold” from the six brokerages that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $37.50.

Several brokerages have recently issued reports on INKT. HC Wainwright raised shares of MiNK Therapeutics from a “neutral” rating to a “buy” rating and set a $35.00 price target for the company in a report on Friday, August 15th. Weiss Ratings restated a “sell (d-)” rating on shares of MiNK Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen cut MiNK Therapeutics to a “strong sell” rating in a report on Saturday, August 23rd. B. Riley upgraded shares of MiNK Therapeutics to a “strong-buy” rating in a research note on Friday, July 18th. Finally, William Blair lowered shares of MiNK Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Friday, July 11th.

MiNK Therapeutics Trading Down 2.3%

Shares of INKT opened at $14.44 on Friday. MiNK Therapeutics has a 52 week low of $4.56 and a 52 week high of $76.00. The firm has a market cap of $65.27 million, a price-to-earnings ratio of -5.01 and a beta of 0.33. The stock has a 50 day moving average of $14.62 and a 200-day moving average of $11.91.

MiNK Therapeutics (NASDAQ:INKT) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.51). On average, sell-side analysts predict that MiNK Therapeutics will post -2.75 earnings per share for the current fiscal year.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.